Immunotherapy for hormone receptor-positive HER2-negative breast cancer

By sjmartinez • December 8, 2024

Cardoso F, Hirshfield KM, Kraynyak KA, Tryfonidis K, Bardia A. Immunotherapy for hormone receptor‒positive HER2-negative breast cancer. NPJ Breast Cancer. 2024 Dec 6;10(1):104. doi: 10.1038/s41523-024-00704-9. PMID: 39643613; PMCID: PMC11624285.

Tags: Hematology/Oncology, Publications

Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen[...]

Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study

Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, Delmas D, Boyault S, Rigal O, Bousrih C, Lévy C, Lerebours F, Di[...]

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply

Bardia A, Schwaederle M, Curigliano G. Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply. N Engl J Med. 2025 Feb 20;392(8):830-831. doi:[...]